Cyclacel Pharmaceuticals (CYCC) 10-Q2012 Q1 Quarterly report

Filed: 15 May 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Amerisource, ascribed, awaiting, Bergen, BRCA, cap, CLL, component, construction, conventional, converge, cured, Dacogen, Dispute, distinguishing, eighteen, exploring, external, formula, hearing, hypomethylating, interrelated, isolation, jury, leukaemia, lymphocytic, modulating, notably, ovarian, Panel, passed, point, predominantly, reclassified, Recombinant, Resolution, resolved, retrospectively, reverse, scenario, scheduling, slightly, split, staffing, Sterling, stipulated, Subtopic, teleconference, unmet, unwilling, Wednesday

Removed: accretion, allocated, alvocidib, announced, approached, AstraZeneca, attributed, audit, behalf, Beiersdorf, Berkeley, Boehringer, Bothell, calculation, captioned, ceased, CEFF, cellular, Cephalon, Certification, clinic, commenced, comparing, competent, consisting, correct, CTEP, customary, daily, dated, deducting, delivered, detail, detect, detrimental, distributing, drew, Dundee, Eisai, EITF, Eli, elimination, ensure, entitle, Entremed, error, exercising, flavopiridol, function, generating, Genzyme, GlaxoSmithKline, good, group, hinder, hindering, hiring, Hospira, identified, immaterial, impede, inclusion, incorrect, increasingly, incremental, indemnification, Induced, inducement, Ingelheim, Institute, interaction, investigational, investor, issuable, Jersey, Johnson, jointly, Kingsbridge, lapsed, lease, lesser, Lilly, limiting, liquidated, locate, mechanism, Merck, molecule, MPM, National, Nerviano, offering, Onconova, onForm, optional, paper, participate, percentage, Pfizer, Piramal, placement, played, practicable, predecessor, pro, promptly, pursuit, qualify, rata, register, registrable, registrant, regulating, remediate, remediation, representing, response, restrictive, restructured, restructuring, retained, Rigel, Roche, role, Seattle, select, selected, sponsored, subscribed, Tekmira, therapeutically, Therapy, thirty, transferred, undeclared, undersigned, Unregistered, unsatisfactory, utilization, Vertex, vested, voted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CYCC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

Certification of Principal Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. s 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Cyclacel Pharmaceuticals, Inc. ( the “Company”) hereby certifies, to such officer’s knowledge, that:

(i) the Quarterly Report on Form10-Q of the Company for the three months ended March 31, 2012 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2012		/s/ Spiro Rombotis
		Spiro Rombotis
		President & Chief Executive Officer